XTL Biopharmaceuticals Ltd (H2K2) - Total Liabilities

Latest as of December 2024: €3.12 Million EUR ≈ $3.64 Million USD

Based on the latest financial reports, XTL Biopharmaceuticals Ltd (H2K2) has total liabilities worth €3.12 Million EUR (≈ $3.64 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of XTL Biopharmaceuticals Ltd to assess how effectively this company generates cash.

XTL Biopharmaceuticals Ltd - Total Liabilities Trend (2016–2024)

This chart illustrates how XTL Biopharmaceuticals Ltd's total liabilities have evolved over time, based on quarterly financial data. Check XTL Biopharmaceuticals Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.

XTL Biopharmaceuticals Ltd Competitors by Total Liabilities

The table below lists competitors of XTL Biopharmaceuticals Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Prominence Energy Limited F:RSX	Germany	€517.52K
Chewathai Public Company Limited BK:CHEWA	Thailand	฿3.00 Billion
Canterbury Resources Ltd AU:CBY	Australia	AU$338.28K
Clean Energy Technologies, Inc. Common Stock NASDAQ:CETY	USA	$7.70 Million
Capelli SA PA:ALCAP	France	€645.01 Million
Rochester Resources Ltd V:RCT	Canada	CA$49.40 Million
XOX Technology Bhd KLSE:0017	Malaysia	RM40.33 Million
Butn Ltd AU:BTN	Australia	AU$95.39 Million

Liability Composition Analysis (2016–2024)

This chart breaks down XTL Biopharmaceuticals Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is XTL Biopharmaceuticals Ltd worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.61	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.57	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.36	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how XTL Biopharmaceuticals Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for XTL Biopharmaceuticals Ltd (2016–2024)

The table below shows the annual total liabilities of XTL Biopharmaceuticals Ltd from 2016 to 2024.

Year	Total Liabilities	Change
2024-12-31	€3.12 Million ≈ $3.64 Million	+1412.14%
2023-12-31	€206.00K ≈ $240.84K	+10.16%
2022-12-31	€187.00K ≈ $218.62K	-85.45%
2021-12-31	€1.28 Million ≈ $1.50 Million	+405.91%
2020-12-31	€254.00K ≈ $296.95K	+9.48%
2019-12-31	€232.00K ≈ $271.23K	-8.30%
2018-12-31	€253.00K ≈ $295.78K	-91.47%
2017-12-31	€2.97 Million ≈ $3.47 Million	+799.09%
2016-12-31	€330.00K ≈ $385.80K	--

About XTL Biopharmaceuticals Ltd

F:H2K2 Germany Biotechnology

Market Cap

$25.22 Million

€21.57 Million EUR

Market Cap Rank

#27762 Global

#2409 in Germany

Share Price

€2.28

Change (1 day)

+23.24%

52-Week Range

€0.45 - €2.80

All Time High

€8.26